PureTech Health PLC
NASDAQ:PRTC

Watchlist Manager
PureTech Health PLC Logo
PureTech Health PLC
NASDAQ:PRTC
Watchlist
Price: 17.55 USD -6.28% Market Closed
Market Cap: 420m USD
Have any thoughts about
PureTech Health PLC?
Write Note

EV/EBIT
Enterprise Value to EBIT

352.9
Current
204.6
Median
4
Industry
Higher than median
Higher than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
352.9
=
Enterprise Value
-38.9B GBX
/
EBIT
-136.4m USD
All Countries
Close
Market Cap EV/EBIT
US
PureTech Health PLC
NASDAQ:PRTC
335.2m USD 352.9
FR
Pharnext SCA
OTC:PNEXF
6T USD -219 507.1
US
Abbvie Inc
NYSE:ABBV
315.4B USD 23.8
US
Amgen Inc
NASDAQ:AMGN
142B USD 30.5
US
Gilead Sciences Inc
NASDAQ:GILD
111.1B USD 9.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
106.2B USD 23
US
Epizyme Inc
F:EPE
94.1B EUR -495.3
AU
CSL Ltd
ASX:CSL
139.2B AUD 25.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.8B USD 17.6
US
Seagen Inc
F:SGT
39.3B EUR -52.4
NL
argenx SE
XBRU:ARGX
38.4B EUR -108.6
EBIT Growth EV/EBIT to Growth
US
PureTech Health PLC
NASDAQ:PRTC
Average EV/EBIT: 69
352.9
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -219 507.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.8
24%
1
US
Amgen Inc
NASDAQ:AMGN
30.5
24%
1.3
US
Gilead Sciences Inc
NASDAQ:GILD
9.8
10%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23
13%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -495.3 N/A N/A
AU
CSL Ltd
ASX:CSL
25.2
16%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.6
12%
1.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -52.4 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -108.6 N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
3.5
2-Years Forward
EV/EBIT
3.3
3-Years Forward
EV/EBIT
3.2